Business Wire

UT-XLEAR

1.11.2021 12:32:10 CET | Business Wire | Press release

Share
Nathan Jones, CEO of Xlear, Inc. Statement in Response to a Lawsuit Filed by the Department of Justice, on Behalf of the United States, Alleging That Certain Statements Made by Xlear Violated the FTC Act and the Consumer Protection Act

Today, Nathan Jones, CEO of Xlear, Inc. released this statement in response to a lawsuit filed by the Department of Justice, on behalf of the United States, alleging that certain statements made by Xlear violated the Federal Trade Commission Act and the Consumer Protection Act:

Last year, the Government published on the website of the National Institutes of Health the results of a clinical trial performed by researchers at Larkin Community Hospital, Florida. The Larkin clinical trial found people who were already sick with COVID-19, who used Xlear nasal spray—and just Xlear nasal spray—cleared the disease and tested negative in half the time of the average COVID-19 case. None of the patients developed severe cases, none required hospitalization. Now the Government is suing Xlear asserting, among other things, that when Xlear tells people about scientific studies, even ones republished by the NIH, we are somehow misleading people and making false claims. It’s nonsensical.

What is more troubling, despite the results of the Larkin trial, and despite the results of a Government-funded Random Clinical Trial done at Vanderbilt University, and despite the findings of yet another Random Clinical Trial done in Georgia, the Government refuses to tell the American people that washing your nose may significantly reduce your risks of getting a severe case of COVID-19, which could result in hospitalization and death.

At the same time, growing numbers of in vitro studies find Xlear, and its components, are: antiviral (blocks adhesion—infection—by COVID-19); virucidal (kills and/or deactivates the COVID-19 virus); and, antibacterial (help prevent pneumonia, a leading COVID-19 co-morbidity). This is real science—done and published by independent medical experts. We believe so strongly in the science we are providing links to these studies here. People should read them for themselves.

In sharp contrast to trying to protect the American public, the Government is doing all in its power to stop Xlear from simply telling the public about the science. It is profoundly ironic that the Government, which now constantly ignores science for political reasons, suggests that it is taking this action against Xlear to somehow protect the people. From what is the Government protecting Americans? From the facts. From the science. From their right to know.

Notwithstanding the Government’s litany of failures in protecting Americans from COVID-19, the Government seeks to pin blame on Xlear, a small company trying to help Americans understand there are other things that you can do that may help to provide additional layer of protection against COVID-19 for you, your friends, and your family. Get vaccinated, wear a mask, social distance, use common-sense, wash your hands—and wash your nose.

The Government tells people to wash their hands; Yet COVID-19 is an upper respiratory illness. Most COVID-19 infections start in the nose. It makes commonsense to wash your nose. People have been using nasal cleansing to fight respiratory illnesses going back thousands of years.

Xlear denies the Government’s allegations. We will vigorously defend against the Government’s case, and, in doing so, defend the science against politics, paternalism, and dogmaticism.

References:
Go , Camille Celeste, Pandav, Krunal, Sanchez-Gonzalez, Marcos A, Ferrer Gustavo, Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series (Nov. 2020), available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645297/
Ferrer, Gustavo, et al, A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro, BioRxiv (Nov. 25, 2020), available at https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full ;
Cannon, Mark, et al, In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2, bioRxiv 2020.12.02.408575, available at https://www.biorxiv.org/content/10.1101/2020.12.02.408575v2.full.pdf+html ;
Ferrer, G., et al., In Vitro Analysis of the Anti-viral Potential of Nasal Spray Constituents Xylitol and Grapefruit Extract plus against SARS-CoV-2, forthcoming in Journal Virus Research;
Kimura, K., et al., Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in nonhospitalized patients with coronavirus disease 2019. Int Forum Allergy Rhinol. 2020; 10: 1325– 1328, available at https://pubmed.ncbi.nlm.nih.gov/32914928/ .
Amy Baxter, et al., Rapid initiation of nasal saline irrigation to reduce morbidity and mortality in COVID+ outpatients: a randomized clinical trial compared to a national dataset, medRxiv 2021.08.16.21262044; doi:https://doi.org/10.1101/2021.08.16.21262044 available at https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v2 ;
Cegolon L, Javanbakht M, Mastrangelo G. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents [published online ahead of print, 2020 Aug 18]. Int J Hyg Environ Health. 2020;230:113605. doi:10.1016/j.ijheh.2020.113605;
Lipworth B, Chan R, RuiWen Kuo C. COVID-19: Start with the nose. J Allergy Clin Immunol. 2020;146(5):1214. doi:10.1016/j.jaci.2020.06.038; Spinelli, M. et al., Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity, The Lancet, Feb. 22, 2020, available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30982-8/fulltext ;
Radulesco T, Lechien JR, Saussez S, Hopkins C, Michel J. Safety and Impact of Nasal Lavages During Viral Infections Such as SARS-CoV-2. Ear Nose Throat J. 2021;100(2_suppl):188S-191S. doi:10.1177/0145561320950491.

Link:

ClickThru

Social Media:

https://www.facebook.com/xylitol.experts

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lattice and NXP Deliver Flexible, Secure Computing Solution for the Industrial Edge10.11.2026 22:00:00 CET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced the Lattice NXP PCIe® Companion solution, jointly enabled and promoted with NXP® Semiconductors. Pairing NXP’s i.MX 95 applications processor with Lattice Nexus™-based FPGAs over PCIe, the solution addresses the real-time connectivity, deterministic I/O, and security challenges in industrial automation, robotics, and intelligent edge applications. The joint solution is available in Lattice CertusPro™-NX or Lattice Certus™-NX configurations as companion chips to NXP i.MX 95 SoC compute processors, deepening a long-standing collaboration between Lattice and NXP spanning industrial, data center, and networking applications. The Lattice FPGA adds low latency, deterministic I/O alongside the NXP applications processor, delivering combined capabilities across real-time processing, AI, and custom I/O to help customers modernize aging designs for new interface standards. It supports e

FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 19:14:00 CET | Press release

PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and painPIMJETMI has shown high objective response rate (ORR) with a manageable safety profileNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significant

Smartsheet Integrates With Claude Sheets, Making It Easy to Start Projects in Claude and Launch Workflows Across Teams with Smartsheet10.11.2026 18:57:00 CET | Press release

New Send to Smartsheet feature moves work started in Claude into Smartsheet, where the Execution Graph connects it to the people, plans and goals that see it through Smartsheet, the AI-powered enterprise work management platform, today announced a new integration with Claude Sheets, the new spreadsheet artifact in Claude from Anthropic, now in beta. With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. There they can put it to work with their team, connected to the plans, projects, people and systems their organization already runs on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110763156/en/ With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. More and more work now begins in a conversation with Claude, and the Smartsheet MCP connector for Claude puts the entire pow

InterSystems Joins Google Cloud as Launch Partner for Gemini for Healthcare10.11.2026 18:00:00 CET | Press release

Integration with InterSystems IRIS FHIR MCP will help healthcare organizations securely connect Gemini to trusted, standards-based health data InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that it will serve as a launch partner for Google Cloud’s Gemini for healthcare. Through the collaboration, Gemini for healthcare will connect to the InterSystems IRIS FHIR Model Context Protocol (MCP) server, enabling healthcare organizations to give AI assistants and agents governed access to FHIR data. The integration will bring together Google Cloud’s Gemini capabilities and the standards-based data access provided by InterSystems IRIS FHIR MCP. InterSystems FHIR MCP serves the open Model Context Protocol directly from a FHIR endpoint, allowing MCP-enabled clients to discover and use FHIR tools for searching, reading, creating, updating, and managing healthcare data. “Healthcare organizations are looking for practical way

Coherent Solutions Launches AKTIV, a Dedicated Fitness and Wellness Technology Business Unit10.11.2026 16:34:00 CET | Press release

Coherent Solutions officially launches AKTIV, a dedicated business unit focused exclusively on fitness and wellness technology. AKTIV brings together over 15 years of fitness industry experience, dedicated leadership, and global engineering capabilities to help fitness and wellness operators and equipment manufacturers compete through technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110242555/en/ Coherent Solutions officially launches AKTIV “We know the fitness and wellness industry and the challenges operators and manufacturers face. With AKTIV, we spend less time defining what needs to be built and more time delivering solutions that improve operations, member experiences, and business performance,” said Vadim Bartlov, Managing Director of AKTIV. AKTIV builds on Coherent Solutions' established work with leading fitness companies, including Life Time, Planet Fitness, Anytime Fitness, Orangetheory, and BowFlex,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye